Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free GUD Stock Alerts

Knight Therapeutics (GUD) Competitors

Knight Therapeutics logo
C$9.90 0.00 (0.00%)
As of 04:00 PM Eastern
Compare

GUD vs. BHC, MJN, CRON, CARA, and DB

Should you buy Knight Therapeutics stock or one of its competitors? Knight Therapeutics's main competitors and comparable companies include Bausch Health Companies (BHC), Cronos Group (MJN), Cronos Group (CRON), Cara Operations (CARA), and Decibel Cannabis (DB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Knight Therapeutics compare to Bausch Health Companies?

Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Bausch Health Companies is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bausch Health CompaniesC$10.85B0.29-C$125.65M-C$2.94N/A
Knight TherapeuticsC$547.31M1.78-C$30.73MC$0.1566.00

Knight Therapeutics has a consensus target price of C$9.50, indicating a potential downside of 4.04%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Knight Therapeutics is more favorable than Bausch Health Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bausch Health Companies
0 Sell rating(s)
3 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

9.6% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 22.3% of Knight Therapeutics shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Bausch Health Companies had 1 more articles in the media than Knight Therapeutics. MarketBeat recorded 1 mentions for Bausch Health Companies and 0 mentions for Knight Therapeutics. Knight Therapeutics' average media sentiment score of 0.95 beat Bausch Health Companies' score of 0.10 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Bausch Health Companies Neutral
Knight Therapeutics Positive

Bausch Health Companies has a beta of 0.707626, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, suggesting that its stock price is 129% less volatile than the broader market.

Knight Therapeutics has a net margin of 2.72% compared to Bausch Health Companies' net margin of -12.02%. Bausch Health Companies' return on equity of 87.57% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Bausch Health Companies-12.02% 87.57% 4.16%
Knight Therapeutics 2.72%1.91%0.51%

Summary

Knight Therapeutics beats Bausch Health Companies on 11 of the 16 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Cronos Group (CVE:MJN) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, media sentiment, risk, profitability, analyst recommendations and valuation.

Knight Therapeutics has a net margin of 2.72% compared to Cronos Group's net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cronos Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Cronos GroupN/A N/A N/A
Knight Therapeutics 2.72%1.91%0.51%

Cronos Group has higher earnings, but lower revenue than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos GroupN/AN/AN/AN/AN/A
Knight TherapeuticsC$547.31M1.78-C$30.73MC$0.1566.00

22.3% of Knight Therapeutics shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Knight Therapeutics has a consensus price target of C$9.50, indicating a potential downside of 4.04%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Cronos Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Cronos Group's average media sentiment score of 1.02 beat Knight Therapeutics' score of 0.95 indicating that Cronos Group is being referred to more favorably in the media.

Company Overall Sentiment
Cronos Group Positive
Knight Therapeutics Positive

Summary

Knight Therapeutics beats Cronos Group on 9 of the 10 factors compared between the two stocks.

How does Knight Therapeutics compare to Cronos Group?

Knight Therapeutics (TSE:GUD) and Cronos Group (TSE:CRON) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, earnings, media sentiment, profitability, dividends, valuation, analyst recommendations and institutional ownership.

Knight Therapeutics has higher revenue and earnings than Cronos Group. Cronos Group is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Knight TherapeuticsC$547.31M1.78-C$30.73MC$0.1566.00
Cronos GroupC$179.09M8.93-C$32.78MC$0.1922.84

Cronos Group has a net margin of 38.95% compared to Knight Therapeutics' net margin of 2.72%. Cronos Group's return on equity of 6.46% beat Knight Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Knight Therapeutics2.72% 1.91% 0.51%
Cronos Group 38.95%6.46%-3.73%

22.3% of Knight Therapeutics shares are owned by institutional investors. Comparatively, 4.2% of Cronos Group shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by company insiders. Comparatively, 46.4% of Cronos Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Knight Therapeutics has a beta of -0.290935, suggesting that its share price is 129% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.29991, suggesting that its share price is 30% more volatile than the broader market.

In the previous week, Knight Therapeutics' average media sentiment score of 0.95 beat Cronos Group's score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Knight Therapeutics Positive
Cronos Group Neutral

Knight Therapeutics presently has a consensus price target of C$9.50, suggesting a potential downside of 4.04%. Cronos Group has a consensus price target of C$4.92, suggesting a potential upside of 13.29%. Given Cronos Group's higher possible upside, analysts plainly believe Cronos Group is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cronos Group
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Cronos Group beats Knight Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Knight Therapeutics compare to Cara Operations?

Cara Operations (TSE:CARA) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Cara Operations has higher earnings, but lower revenue than Knight Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cara OperationsN/AN/AN/AN/AN/A
Knight TherapeuticsC$547.31M1.78-C$30.73MC$0.1566.00

Knight Therapeutics has a consensus price target of C$9.50, indicating a potential downside of 4.04%. Given Cara Operations' higher possible upside, equities research analysts clearly believe Cara Operations is more favorable than Knight Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cara Operations
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

22.3% of Knight Therapeutics shares are owned by institutional investors. 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Knight Therapeutics' average media sentiment score of 0.95 beat Cara Operations' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Cara Operations Neutral
Knight Therapeutics Positive

Knight Therapeutics has a net margin of 2.72% compared to Cara Operations' net margin of 0.00%. Knight Therapeutics' return on equity of 1.91% beat Cara Operations' return on equity.

Company Net Margins Return on Equity Return on Assets
Cara OperationsN/A N/A N/A
Knight Therapeutics 2.72%1.91%0.51%

Summary

Knight Therapeutics beats Cara Operations on 9 of the 10 factors compared between the two stocks.

How does Knight Therapeutics compare to Decibel Cannabis?

Decibel Cannabis (CVE:DB) and Knight Therapeutics (TSE:GUD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Decibel Cannabis has a beta of 0.321627, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Knight Therapeutics has a beta of -0.290935, suggesting that its share price is 129% less volatile than the broader market.

In the previous week, Knight Therapeutics' average media sentiment score of 0.95 beat Decibel Cannabis' score of 0.00 indicating that Knight Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Decibel Cannabis Neutral
Knight Therapeutics Positive

0.0% of Decibel Cannabis shares are owned by institutional investors. Comparatively, 22.3% of Knight Therapeutics shares are owned by institutional investors. 1.1% of Decibel Cannabis shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Knight Therapeutics has a net margin of 2.72% compared to Decibel Cannabis' net margin of -3.78%. Knight Therapeutics' return on equity of 1.91% beat Decibel Cannabis' return on equity.

Company Net Margins Return on Equity Return on Assets
Decibel Cannabis-3.78% -1.05% 3.04%
Knight Therapeutics 2.72%1.91%0.51%

Decibel Cannabis currently has a consensus price target of C$0.18, suggesting a potential downside of 89.71%. Knight Therapeutics has a consensus price target of C$9.50, suggesting a potential downside of 4.04%. Given Knight Therapeutics' higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Decibel Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Decibel Cannabis
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
3.50
Knight Therapeutics
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00

Decibel Cannabis has higher earnings, but lower revenue than Knight Therapeutics. Decibel Cannabis is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Decibel CannabisC$127.08M0.51-C$1.03M-C$0.15N/A
Knight TherapeuticsC$547.31M1.78-C$30.73MC$0.1566.00

Summary

Knight Therapeutics beats Decibel Cannabis on 10 of the 15 factors compared between the two stocks.

Get Knight Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GUD vs. The Competition

Export
MetricKnight TherapeuticsPharmaceuticals IndustryHealthcare SectorTSE Exchange
Market CapC$972.50MC$12.40BC$7.12BC$12.64B
Dividend YieldN/A2.59%2.54%6.25%
P/E Ratio66.00794.77272.3539.59
Price / Sales1.78756.54696.039.92
Price / Cash3.8590.2677.0782.29
Price / Book1.2210.5810.764.72
Net Income-C$30.73MC$2.82BC$3.48BC$299.09M
7 Day Performance2.38%-2.26%-1.38%0.35%
1 Month Performance1.43%2.41%2.17%0.47%
1 Year Performance53.97%4.77%20.74%26.68%

Knight Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GUD
Knight Therapeutics
0.8764 of 5 stars		C$9.90
flat		C$9.50
-4.0%		+53.5%C$972.50MC$547.31M66.00725
BHC
Bausch Health Companies
0.6179 of 5 stars		C$9.25
-2.2%		N/A-12.5%C$3.46BC$10.85BN/A19,900
MJN
Cronos Group
N/AC$12.15
-1.9%		N/A+0.0%C$1.73BN/AN/A7,600
CRON
Cronos Group
1.8402 of 5 stars		C$4.45
-0.4%		C$4.92
+10.5%		+27.4%C$1.64BC$179.09M23.42450
CARA
Cara Operations
N/AN/AN/AN/AC$1.62BN/AN/A80

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (TSE:GUD) was last updated on 9/9/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel